AbbVie Inc. (ABBV) Stock Competitors & Peer Comparison
See (ABBV) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ABBV | $253.38 | -0.44% | 447.8B | 24.87 | $10.19 | +2.70% |
| LLY | $1,146.85 | -2.74% | 1.1T | 38.98 | $29.42 | +0.56% |
| JNJ | $248.82 | -1.67% | 599B | 23.19 | $10.73 | +2.10% |
| MRK | $124.41 | -2.42% | 307.3B | 22.74 | $5.47 | +2.69% |
| NVS | $149.56 | -2.73% | 285.3B | 17.21 | $8.69 | +3.16% |
| NVO | $49.61 | -1.41% | 220.6B | 12.32 | $4.03 | +3.63% |
| AMGN | $364.17 | -0.58% | 196.5B | 16.48 | $22.10 | +2.69% |
| GILD | $133.21 | -0.80% | 165.4B | 15.92 | $8.37 | +2.42% |
| PFE | $24.75 | -1.20% | 141B | 8.09 | $3.06 | +6.95% |
| AZN | $164.52 | -2.59% | 127.5B | 17.77 | $9.26 | +1.94% |
Stock Comparison
ABBV vs LLY Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, ABBV is priced at $253.38, while LLY trades at $1,146.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas LLY's P/E ratio is 38.98. In terms of profitability, ABBV's ROE is +0.68%, compared to LLY's ROE of +1.01%. Regarding short-term risk, ABBV is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check LLY's competition here
ABBV vs JNJ Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, JNJ has a market cap of 599B. Regarding current trading prices, ABBV is priced at $253.38, while JNJ trades at $248.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas JNJ's P/E ratio is 23.19. In terms of profitability, ABBV's ROE is +0.68%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, ABBV is less volatile compared to JNJ. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check JNJ's competition here
ABBV vs MRK Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, MRK has a market cap of 307.3B. Regarding current trading prices, ABBV is priced at $253.38, while MRK trades at $124.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas MRK's P/E ratio is 22.74. In terms of profitability, ABBV's ROE is +0.68%, compared to MRK's ROE of +0.18%. Regarding short-term risk, ABBV is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check MRK's competition here
ABBV vs NVS Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, NVS has a market cap of 285.3B. Regarding current trading prices, ABBV is priced at $253.38, while NVS trades at $149.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas NVS's P/E ratio is 17.21. In terms of profitability, ABBV's ROE is +0.68%, compared to NVS's ROE of +0.32%. Regarding short-term risk, ABBV is less volatile compared to NVS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check NVS's competition here
ABBV vs NVO Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, NVO has a market cap of 220.6B. Regarding current trading prices, ABBV is priced at $253.38, while NVO trades at $49.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas NVO's P/E ratio is 12.32. In terms of profitability, ABBV's ROE is +0.68%, compared to NVO's ROE of +0.66%. Regarding short-term risk, ABBV is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check NVO's competition here
ABBV vs AMGN Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, AMGN has a market cap of 196.5B. Regarding current trading prices, ABBV is priced at $253.38, while AMGN trades at $364.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas AMGN's P/E ratio is 16.48. In terms of profitability, ABBV's ROE is +0.68%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, ABBV is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check AMGN's competition here
ABBV vs GILD Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, GILD has a market cap of 165.4B. Regarding current trading prices, ABBV is priced at $253.38, while GILD trades at $133.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas GILD's P/E ratio is 15.92. In terms of profitability, ABBV's ROE is +0.68%, compared to GILD's ROE of +0.42%. Regarding short-term risk, ABBV is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check GILD's competition here
ABBV vs PFE Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, PFE has a market cap of 141B. Regarding current trading prices, ABBV is priced at $253.38, while PFE trades at $24.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas PFE's P/E ratio is 8.09. In terms of profitability, ABBV's ROE is +0.68%, compared to PFE's ROE of +0.08%. Regarding short-term risk, ABBV is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check PFE's competition here
ABBV vs AZN Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, AZN has a market cap of 127.5B. Regarding current trading prices, ABBV is priced at $253.38, while AZN trades at $164.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas AZN's P/E ratio is 17.77. In terms of profitability, ABBV's ROE is +0.68%, compared to AZN's ROE of +0.22%. Regarding short-term risk, ABBV is less volatile compared to AZN. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check AZN's competition here
ABBV vs BMY Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, BMY has a market cap of 122.9B. Regarding current trading prices, ABBV is priced at $253.38, while BMY trades at $60.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas BMY's P/E ratio is 10.15. In terms of profitability, ABBV's ROE is +0.68%, compared to BMY's ROE of +0.39%. Regarding short-term risk, ABBV is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check BMY's competition here
ABBV vs SNY Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, SNY has a market cap of 107.4B. Regarding current trading prices, ABBV is priced at $253.38, while SNY trades at $43.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas SNY's P/E ratio is 9.73. In terms of profitability, ABBV's ROE is +0.68%, compared to SNY's ROE of +0.11%. Regarding short-term risk, ABBV is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for ABBV.Check SNY's competition here
ABBV vs GSK Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, GSK has a market cap of 100.2B. Regarding current trading prices, ABBV is priced at $253.38, while GSK trades at $50.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas GSK's P/E ratio is 10.81. In terms of profitability, ABBV's ROE is +0.68%, compared to GSK's ROE of +0.28%. Regarding short-term risk, ABBV is less volatile compared to GSK. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check GSK's competition here
ABBV vs ZTS Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, ZTS has a market cap of 31.9B. Regarding current trading prices, ABBV is priced at $253.38, while ZTS trades at $76.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas ZTS's P/E ratio is 11.78. In terms of profitability, ABBV's ROE is +0.68%, compared to ZTS's ROE of +0.62%. Regarding short-term risk, ABBV is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check ZTS's competition here
ABBV vs BIIB Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, BIIB has a market cap of 29.5B. Regarding current trading prices, ABBV is priced at $253.38, while BIIB trades at $199.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas BIIB's P/E ratio is 12.62. In terms of profitability, ABBV's ROE is +0.68%, compared to BIIB's ROE of +0.08%. Regarding short-term risk, ABBV is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check BIIB's competition here
ABBV vs HZNP Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, ABBV is priced at $253.38, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas HZNP's P/E ratio is 61.86. In terms of profitability, ABBV's ROE is +0.68%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, ABBV is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for ABBV.Check HZNP's competition here
ABBV vs GRFS Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, GRFS has a market cap of 6.4B. Regarding current trading prices, ABBV is priced at $253.38, while GRFS trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas GRFS's P/E ratio is 8.74. In terms of profitability, ABBV's ROE is +0.68%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, ABBV is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check GRFS's competition here
ABBV vs OGN Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, OGN has a market cap of 3.5B. Regarding current trading prices, ABBV is priced at $253.38, while OGN trades at $13.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas OGN's P/E ratio is 4.03. In terms of profitability, ABBV's ROE is +0.68%, compared to OGN's ROE of +0.30%. Regarding short-term risk, ABBV is more volatile compared to OGN. This indicates potentially higher risk in terms of short-term price fluctuations for ABBV.Check OGN's competition here
ABBV vs CELG-RI Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, CELG-RI has a market cap of 204M. Regarding current trading prices, ABBV is priced at $253.38, while CELG-RI trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, ABBV's ROE is +0.68%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, ABBV is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check CELG-RI's competition here
ABBV vs SCLXW Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, SCLXW has a market cap of 67.8M. Regarding current trading prices, ABBV is priced at $253.38, while SCLXW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas SCLXW's P/E ratio is -0.01. In terms of profitability, ABBV's ROE is +0.68%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, ABBV is more volatile compared to SCLXW. This indicates potentially higher risk in terms of short-term price fluctuations for ABBV.Check SCLXW's competition here
ABBV vs SCLX Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, SCLX has a market cap of 64.9M. Regarding current trading prices, ABBV is priced at $253.38, while SCLX trades at $7.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas SCLX's P/E ratio is -0.20. In terms of profitability, ABBV's ROE is +0.68%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, ABBV is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check SCLX's competition here
ABBV vs CTOR Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, CTOR has a market cap of 56.7M. Regarding current trading prices, ABBV is priced at $253.38, while CTOR trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas CTOR's P/E ratio is -1.30. In terms of profitability, ABBV's ROE is +0.68%, compared to CTOR's ROE of -0.99%. Regarding short-term risk, ABBV is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check CTOR's competition here
ABBV vs MIRA Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, MIRA has a market cap of 38.7M. Regarding current trading prices, ABBV is priced at $253.38, while MIRA trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas MIRA's P/E ratio is -0.63. In terms of profitability, ABBV's ROE is +0.68%, compared to MIRA's ROE of -1.41%. Regarding short-term risk, ABBV is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check MIRA's competition here
ABBV vs CRXT Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, ABBV is priced at $253.38, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas CRXT's P/E ratio is -0.02. In terms of profitability, ABBV's ROE is +0.68%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, ABBV is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check CRXT's competition here
ABBV vs BDSIW Comparison July 2026
ABBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 447.8B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, ABBV is priced at $253.38, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 24.87, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, ABBV's ROE is +0.68%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, ABBV is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for ABBV.Check BDSIW's competition here